Shalini S Sharma NEW DELHI: On March 19, the pharmaceutical landscape in India didn’t just shift; it underwent a tectonic reorganisation. For years, the “miracle” weight-loss molecule, semaglutide, had been the exclusive playground of the wealthy — a luxury accessible only to those who could afford the steep Rs 10,000+ monthly price tag of the…


